Clinical trials
Non-small Cell Carcinoma clinical trials
Below are recruiting non-small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 525 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06476093Recruiting
Radiation plus anlotinib for lung cancer brain spread
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
Lianyungang, JiangsuAges 18–80 - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+ - NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Sarasota, FloridaAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Tucson, ArizonaAges 18 years+ - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Phoenix, ArizonaAges 18 years+ - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06554613RecruitingPhase 2
Olanzapine with first-line immunotherapy for advanced lung cancer trial
This trial tests whether adding the drug olanzapine to standard first-line immunotherapy (with or without chemotherapy) can help people with advanced lung cancer that does not have an EGFR mutation. It aims to improve treatment outcomes and quality of life.
Nanchang, JiangxiAges 18–75 - NCT06566443RecruitingPhase 1
Honokiol for early-stage lung cancer before surgery
This trial tests a natural compound called honokiol in people with early-stage non-small cell lung cancer who are scheduled for surgery. The goal is to see if honokiol can help shrink or control the tumor before it is removed.
Houston, TexasAges 18 years+ - NCT06567015RecruitingPhase 1/Phase 2
STX-241 for advanced EGFR-mutant lung cancer after TKI failure
This trial tests an experimental drug called STX-241 for people with a specific type of advanced lung cancer (NSCLC) that has an EGFR mutation (exon 19 deletion or L858R) and has stopped responding to a third-generation EGFR inhibitor (like osimertinib). The drug aims to target a new mutation, C797X, that sometimes appears after osimertinib stops working.
Nashville, TennesseeAges 18 years+ - NCT06579196RecruitingPhase 1/Phase 2
Trabedersen with pembrolizumab for newly diagnosed advanced lung cancer
This trial tests a new drug, trabedersen, combined with the immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that hasn't been treated yet. It's for patients whose tumors have a protein called PD-L1 (at least 1%) and who are generally well enough to participate.
Omaha, NebraskaAges 19 years+ - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT06582940RecruitingPhase 2
MRI-guided radiation for lung cancer with brain metastases
This trial tests a new way to deliver radiation to brain metastases from non-small cell lung cancer, using MRI scans to guide the treatment and reduce the area exposed. The goal is to see if this approach is safe and effective while possibly lowering side effects.
Guangzhou, GuangdongAges 18–75 - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06598527RecruitingPhase 3
Radiation and immunotherapy before surgery for lung cancer
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Guangzhou, GuangdongAges 18–75 - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT06139627Recruiting
Geriatric assessment for older adults with lung cancer getting chemotherapy and radiation
This trial tests whether a special geriatric assessment can help manage side effects for adults aged 60 and older with non-small cell lung cancer who are starting a new treatment plan that includes chemotherapy and radiation. It aims to improve quality of life and treatment outcomes.
Duarte, CaliforniaAges 60 years+ - NCT07690917Recruiting
New PET scanner study for people with cancer
This trial tests a new PET scanner that may help doctors see where cancer is in your body more clearly. It is for adults with lung, prostate, or head and neck cancer who are already scheduled for a PET-CT scan at Memorial Sloan Kettering.
Basking Ridge, New JerseyAges 18 years+ - NCT07242547RecruitingPhase 2
Tarlatamab maintenance for limited-stage small cell lung cancer
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
Albacete, AlbaceteAges 18 years+ - NCT06604689Recruiting
AI-guided brain radiation for EGFR-mutant lung cancer with brain mets
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
San Diego, CaliforniaAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Daphne, AlabamaAges 18 years+
Hear when a new Non-small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-small cell carcinoma?
- Yes. Clin2 currently lists 525 recruiting non-small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.